benzoxazoles has been researched along with Amyloid Neuropathy Type 1 in 140 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 80 (57.14) | 24.3611 |
| 2020's | 60 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Barbarossa, A; Capucci, A; Casella, M; Ciliberti, G; Dello Russo, A; Falanga, U; Guerra, F; Principi, S; Silenzi, M; Stronati, G; Urbinati, A | 1 |
| Damy, T; Grogan, M; Gundapaneni, B; Hanna, M; Maurer, MS; Stewart, M; Sultan, MB | 1 |
| Drachman, BM; Ebede, B; Elliott, P; Gottlieb, SS; Gundapaneni, B; Hoffman, JE; Hummel, SL; Lenihan, DJ; Li, B; Shah, SJ; Sultan, MB | 2 |
| Brogneaux, C; Grayet, D; Jackers, L; Lacremans, D; Legrand, D; Magnée, M; Nyssen, A; Pirotte, I | 1 |
| Assmus, B; Bulinski, C; Discher, T; Krämer, HH; Rutsatz, W | 1 |
| Bhambri, R; Nativi-Nicolau, J; Rozenbaum, MH; Tran, D | 1 |
| Aguirre, MA; Calandra, CR; Carretero, M; Conti, E; Lautre, A; León-Cejas, L; Negro, A; Nucifora, EM; Posadas-Martínez, ML; Reisin, R; Rugiero, M; Sáez, MS; Salutto, V; Sorroche, P | 1 |
| Aguirre, MA; Baratta, S; Belziti, CA; Carretero, M; Costabel, JP; Dumont, CA; Fernández, A; Higa, C; Negro, A; Nucifora, EM; Perez de Arenaza, D; Posadas-Martínez, ML; Quiroga, A; Rivas, C; Streitenberg, GM; Villanueva, E; Volberg, VI | 1 |
| Bonderman, D; Rettl, R | 1 |
| Baba, Y; Hamada, T; Hirota, T; Kitaoka, H; Kubo, T; Miyagawa, K; Noguchi, T; Ochi, Y; Sugiura, K; Yamasaki, N | 1 |
| Gomez-Valencia, J; Malhotra, S; Mekritthikrai, R | 1 |
| Elliott, P; Gundapaneni, B; Sultan, MB | 1 |
| Baldovino, S; Costanzo, P; Roccatello, D | 1 |
| Cuddy, SAM | 1 |
| Casey, M; Li, H; Rozenbaum, M; Sultan, MB | 1 |
| Mitchell, JD; Rater, M; Schiffer, W; Zaghlol, R | 1 |
| Balasubramanian, SS; Gaznabi, S; Hussain, K; Iqbal, SH; Kwak, E; Macrinici, V; Minga, I; Pursnani, A; Sarswat, N; Wang, CH; Wathen, L | 1 |
| Anselmo, J; Coelho, T; Fernandes, J; Kelly, JW; Mesgarzadeh, JS; Monteiro, C; Novais, M; Powers, DL; Powers, ET; Rodrigues, C | 1 |
| Fukuda, D; Hara, T; Ise, T; Kadota, M; Kawabata, Y; Kusunose, K; Matsuura, T; Osaki, Y; Saijo, Y; Sata, M; Soeki, T; Tserensonom, M; Ueno, R; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K; Yamazaki, H | 1 |
| Bulawa, C; Fleming, J; Li, Z; Maurer, TS; Moody, AT; Tess, DA | 1 |
| Coelho, T; Jaeger, M; Kelly, JW; Powers, ET; Tsai, FJ | 1 |
| Adams, D; Algalarrondo, V; Benmalek, A; Cauquil, C; Echaniz-Laguna, A; Eliahou, L; Kounis, I; Piekarski, E; Rousseau, A; Rouzet, F; Samuel, D; Slama, MS; Socie, P | 1 |
| Czepluch, F | 1 |
| Cruz, MW | 1 |
| Aschenbrenner, DS | 1 |
| Chang, Y; Huang, SJ; Lin, KP; Liu, YT; Ricardo, F; Wu, PH; Yen, YJ; Yu, TY | 1 |
| Gospodinova, M; Kirov, A; Nakov, R; Nakov, V; Sarafov, S; Todorov, T; Todorova, A; Tournev, I | 1 |
| Ando, Y; Endo, J; Fukuda, K; Inomata, T; Isobe, M; Izumiya, Y; Kuwahara, K; Nakamura, K; Sano, M; Sekijima, Y; Tahara, N; Tsujita, K; Tsutsui, H; Ueda, M | 1 |
| Murohara, T; Okumura, T | 1 |
| Gurwitz, JH; Maurer, MS | 2 |
| Björkenheim, A; Szabó, B; Sztaniszláv, ÁJ | 1 |
| Paton, DM | 1 |
| Maurer, MS; Rubin, J | 1 |
| Amass, L; Cameron, C; Salvo, EM; Samjoo, IA; Stewart, M; Tran, D | 1 |
| Arnold, SV; Baron, SJ; Bellows, BK; Cohen, DJ; Kazi, DS; Maurer, MS; Shah, SJ; Shen, C; Sperry, BW; Spertus, JA; Yeh, RW | 2 |
| Le, VH; Lockwood, PA; O'Gorman, MT; Patterson, TA; Riley, S; Sultan, MB; Tankisheva, E; Wang, Q | 1 |
| Cavallaro, T; Fabrizi, GM; Magrinelli, F; Manganelli, F; Santoro, L; Tamburin, S; Zanette, G | 1 |
| Coyle, ML; Cuddy, SAM; Falk, RH | 1 |
| Magomedov, MM; Nasonova, SN; Osmolovskaya, YF; Saidova, MA; Tereschenko, SN; Zhirov, IV | 1 |
| Brum, M; Caetano, A; Casanova, I; Conceição, I; de Carvalho, M; Díaz, A | 1 |
| Hale, C; Lin, H; Marantz, JL; Merkel, M | 1 |
| Cristóbal Gutiérrez, H; Gómez Gómez, D; Martín Vega, MÁ; Pelayo-Negro, AL; Valero Domínguez, M | 1 |
| Adams, D; Slama, M | 1 |
| Ando, Y; Hirano, Y; Ishii, T; Matsumoto, N; Sekijima, Y; Takata, A; Ueda, M | 1 |
| Kelly, JW; Nelson, LT; Paxman, RJ; Powers, ET; Webb, B; Xu, J | 1 |
| Audia, S; Damy, T; Eicher, JC | 1 |
| Dou, Y; Ge, S; Lo, GV; Yuan, S; Zhang, Q; Zhang, W; Zhou, S | 1 |
| Almeida, AR; Azevedo, O; Bento, D; Correia, E; Cruz, I; Lopes, LR; Lourenço, C; Marques, N | 1 |
| Kemner, J; Parasuraman, B; Rozenbaum, MH | 1 |
| Damy, T; Garcia-Pavia, P; Gundapaneni, B; Hanna, M; Judge, DP; Merlini, G; Patterson, TA; Riley, S; Schwartz, JH; Sultan, MB; Witteles, R | 1 |
| Abulizi, M; Audard, V; Bézard, M; Canoui-Poitrine, F; Damy, T; Deux, JF; El Karoui, K; Fanen, P; Funalot, B; Galat, A; Gendre, T; Guendouz, S; Itti, E; Kharoubi, M; Lefaucheur, JP; Moktefi, A; Oghina, S; Planté-Bordeneuve, V; Poullot, E; Teiger, E; Zaroui, A | 1 |
| Damy, T; Grogan, M; Gundapaneni, B; Hanna, M; Maurer, MS; Patterson, TA; Schwartz, JH; Stewart, M; Sultan, MB | 1 |
| Harnisch, L; Huh, Y; Nicholas, T; Riley, S | 1 |
| Benbrahim, M; Hughes, D; Norman, K; Sanchorawala, V; Siddiqi, OK | 1 |
| Gundapaneni, B; Januzzi, JL; López-Sendón, J; Miller, AB; O'Neill, BJ; Patterson, TA; Sultan, MB | 1 |
| Galan, L; Gonzalez-Moreno, J; Lebeau, P; Mallaina, P; Martínez-Sesmero, JM; Muñoz-Beamud, F; Peral, C; Rozenbaum, MH; Santos-Rubio, MD; Stewart, M; Tarilonte, P; Tran, D | 1 |
| Kittleson, MM; Stern, LK | 1 |
| Boucher, M; Harnisch, LO; Riley, S; Vong, C | 1 |
| Tian, Z; Zhang, SY | 1 |
| Bhambri, R; Garcia, A; Grima, D; Heeg, B; Li, B; Masri, A; Postma, M; Rozenbaum, MH; Stewart, M; Tran, D | 1 |
| Griffin, JM; Maurer, MS; Rosenblum, H | 1 |
| DeLuca, A; Einstein, AJ; Elias, P; Griffin, JM; Johnson, LL; Kinkhabwala, M; Maurer, MS; Pandey, S; Poterucha, TJ; Ruberg, FL | 1 |
| Katsuno, M; Koike, H | 1 |
| Gamino, D; Goldsmith, J; Griffin, JM; Guadalupe, S; Helmke, S; Maurer, MS; Rosenblum, HR; Saith, SE; Santos, JL; Teruya, S | 1 |
| Amass, L; Gundapaneni, B; Keohane, D; Schwartz, J; Stewart, M | 1 |
| Clarke, A; Mendes, Á; Sequeiros, J; Sousa, L | 1 |
| Ando, Y; Iijima, M; Ikeda, S; Ikeda, SI; Katsuno, M; Kawagashira, Y; Koike, H; Misumi, Y; Sobue, G; Takahashi, M | 1 |
| Alves, C; Beirão, I; Cardoso, M; Coelho, T; Lobato, L; Rocha, A; Silva, A; Teles, P | 1 |
| Cruz, MW; Elliott, P; Flynn, A; Gundapaneni, B; Hahn, C; Maurer, MS; Merlini, G; Rapezzi, C; Riley, S; Schwartz, J; Shah, SJ; Sultan, MB | 1 |
| Amass, L; Barroso, FA; Ebede, B; Judge, DP; Li, H; Stewart, M; Sultan, MB | 1 |
| Ahn, S; Choi, S; Hyun, HC; Jang, E; Jeong, JW; Joo, SH; Kim, S; Koo, TS; Lee, KR | 1 |
| Matsushima, M; Sakakibara, M; Sasaki, H; Shimamura, T; Tsuda, M; Yabe, I | 1 |
| Gundapaneni, BK; Keohane, DJ; Schwartz, JH; Sultan, MB | 1 |
| Ando, Y; Ikeda, T; Masuda, T; Misumi, Y; Shinriki, S; Ueda, M; Yamashita, T | 1 |
| Ando, Y; Ishii, T; Koike, H; Misawa, S; Sekijima, Y; Ueda, M | 1 |
| Bianchi, A; Mascalchi, M; Pastorelli, F; Rapezzi, C; Salvi, F; Vella, A; Volpe, R | 1 |
| Castro, J; Conceição, I; de Carvalho, M; Miranda, B | 1 |
| Coelho, T; Ferreira, N; Kelly, JW; Martins da Silva, A; Mesgarzadeh, J; Monteiro, C; Novais, M | 1 |
| Kristen, AV | 1 |
| Barsdorf, AI; Damy, T; Drachman, BM; Elliott, PM; Grogan, M; Gundapaneni, B; Hanna, M; Huber, P; Judge, DP; Kristen, AV; Maurer, MS; Merlini, G; Patterson, TA; Rapezzi, C; Riley, S; Schumacher, J; Schwartz, JH; Shah, SJ; Stewart, M; Sultan, MB; Waddington-Cruz, M; Witteles, R | 1 |
| Ando, Y; Ikeda, N; Kato, TS; Maurer, MS; Tanno, K | 1 |
| Coelho, T; Conceição, I; Costa, J; de Carvalho, M; Inês, M; Soares, M | 1 |
| Barreira, AA; Bulle, AS; França, MC; Freitas, MRG; Gondim, FAA; Marques, W; Marrone, CD; Nascimento, OJM; Pinto, MV; Pupe, C; Rotta, FT; Waddington-Cruz, M | 1 |
| Amaki, M; Amano, M; Hamatani, Y; Hasegawa, T; Ishibashi-Ueda, H; Izumi, C; Kanzaki, H; Morita, Y; Ohta-Ogo, K; Okada, A; Sekijima, Y; Shimazaki, C; Shintani, Y; Takahama, H; Yasuda, S; Yazaki, M; Yoshinaga, T | 1 |
| Agarwal, S; Betts, M; Chitnis, M; Fahrbach, K; Gollob, J; Lin, H; Planté-Bordeneuve, V; Polydefkis, M | 1 |
| Ando, Y; Hashimoto, T; Hiroe, M; Kawamura, S; Yamamoto, H; Yamashita, T; Yokochi, T | 1 |
| Maurer, MS; Rapezzi, C; Sultan, MB | 1 |
| Manion, C; Sharma, UC | 1 |
| Falk, RH | 1 |
| Brannagan, T; Buades-Reinés, J; Buxbaum, JN; Cisneros, E; Conceicao, I; Imai, A; Kyriakides, T; Merlini, G; Obici, L; Plante-Bordeneuve, V; Rousseau, A; Sekijima, Y; Waddington Cruz, M; Yamada, M | 1 |
| Elliott, PM; Lorenzini, M | 1 |
| Castro, J; Conceição, I; Costa, J; de Castro, I | 1 |
| Abate, E; Ali, M; Bigalke, B; de Vecchis, R; Mammadov, M; Matiakis, M; Mavrogeni, S; Melnyk, H; Noutsias, M; Rigopoulos, AG; Torky, AR; Vogt, A; Wohlgemuth, W | 1 |
| Buxbaum, JN | 1 |
| Hineno, A; Ichikawa, T; Ikeda, SI; Makino, M | 1 |
| Deeks, ED; Lamb, YN | 1 |
| Aimo, A; Barison, A; Castiglione, V; Emdin, M; Fontana, M; Giannoni, A; Merlini, G; Passino, C; Perfetto, F; Rapezzi, C; Seferović, PM; Vergaro, G | 1 |
| Cameron, C; Salvo, EM; Samjoo, IA; Tran, D | 1 |
| Agarwal, S; Betts, M; Chitnis, M; Fahrbach, K; Lin, H; Polydefkis, M | 1 |
| Gagliardi, C; Milandri, A; Rapezzi, C | 1 |
| Anselmo, J; Brighty, GJ; Coelho, T; Fernandes, J; Kelly, JW; Mesgazardeh, JS; Monteiro, C; Novais, M; Powers, DL; Powers, ET; Rodrigues, C | 1 |
| Bokhari, S; Damy, T; Elliott, PM; Falk, RH; Fine, NM; Garcia-Pavia, P; Gospodinova, M; Obici, L; Rapezzi, C; Witteles, RM | 1 |
| Autore, C; Canepa, M; Cappelli, F; Milandri, A; Mussinelli, R; Musumeci, B; Perfetto, F; Perlini, S; Rapezzi, C; Tini, G | 1 |
| Merkies, IS | 1 |
| Adams, D; Cauquil, C; Théaudin, M | 1 |
| Adams, D; Ducot, B; Lacroix, C; Lozeron, P; Mincheva, Z; Théaudin, M | 1 |
| Chan, J; Coelho, T; Conceiçao, I; Cruz, MW; da Silva, AM; Grogan, DR; Kelly, JW; Labaudinière, R; Maia, LF; Packman, J; Planté-Bordeneuve, V; Schmidt, HH; Suhr, OB; Trigo, P | 1 |
| Nencetti, S; Orlandini, E; Rossello, A | 1 |
| Grogan, DR; Judge, DP; Merlini, G; Obici, L; Packman, J; Perlini, S; Planté-Bordeneuve, V; Schmidt, H; Tripp, T | 1 |
| Adams, D; Algalarrondo, V; Cauquil, C; Slama, M; Théaudin, M | 1 |
| Sekijima, Y | 4 |
| Scott, LJ | 1 |
| Castaño, A; Drachman, BM; Judge, D; Maurer, MS | 1 |
| Acker, T; Haverkamp, T; Kimmich, C; Krämer, HH; Röcken, C; Schänzer, A; Weidner, I | 1 |
| Aarts, J; Berthet, K; Damy, T; Judge, DP; Kristen, AV; Li, H | 1 |
| Aarts, J; Falk, RH; Grogan, DR; Judge, DP; Lombardo, I; Maurer, MS; Mundayat, R; Packman, J; Quyyumi, AA | 1 |
| Ackermann, E; Dubrey, S; Gillmore, J | 1 |
| Ando, Y; Baba, M; Honda, M; Inomata, Y; Kon, T; Misumi, Y; Nishijima, H; Obayashi, K; Suzuki, C; Tomiyama, M | 1 |
| Baranczak, A; Cho, Y; Helmke, S; Horn, EM; Kelly, JW; Maurer, MS; Teruya, S | 1 |
| Adams, D; Algalarrondo, V; Beaudonnet, G; Cauquil, C; Labeyrie, C; Théaudin, M | 1 |
| Ando, Y; Ikeda, S; Machii, K; Misumi, Y; Morita, H; Obayashi, K; Ohta, M; Sekijima, Y; Takata, A; Ueda, M; Yamashita, T | 1 |
| Bisogni, G; Calabrese, D; Cavallaro, T; Cortese, A; Fabrizi, GM; Gemelli, C; Gentile, L; Grandis, M; Lozza, A; Luigetti, M; Manganelli, F; Mauro, A; Mazzeo, A; Obici, L; Pareyson, D; Perlini, S; Piscosquito, G; Pradotto, LG; Russo, M; Sabatelli, M; Santoro, L; Schenone, A; Stancanelli, C; Vita, G | 1 |
| Alvarez, R; Bettencourt, BR; Borland, TD; Butler, JS; Chan, A; Chen, Q; Costelha, S; Fishman, S; Fitzgerald, K; Foster, DJ; Gonçalves, P; Manoharan, M; Meyers, RE; Milstein, S; Nochur, SV; Qin, J; Rajeev, KG; Sah, DW; Saraiva, MJ; Willoughby, JL; Zimmermann, TS | 1 |
| Bettini, M; Chaves, M; Cristiano, E; Marciano, S; Rugiero, M; Sáez, S | 1 |
| Amass, L; Gundapaneni, B; Keohane, D; Li, H; Schwartz, J; Waddington Cruz, M | 1 |
| Buxbaum, JN; Coelho, T; Gelbart, T; Kelly, JW; Kurian, SM; Novais, M; Salomon, DR; Whisenant, T | 1 |
| Beirão, JM; Casal, I; Monteiro, S | 1 |
| Ayache, SS; Azoulay, D; Damy, T; Feray, C; Gorram, F; Le Corvoisier, P; Lefaucheur, JP; Nordine, T; Planté-Bordeneuve, V; Salhi, H | 1 |
| Miyazaki, Y | 1 |
| Adams, D; Samuel, D; Slama, M | 1 |
| de Lartigue, J | 1 |
| Chalk, C | 1 |
| Campistol, JM; Chan, J; Coelho, T; Conceição, IM; Grogan, DR; Kelly, JW; Labaudinière, R; Lozeron, P; Maia, LF; Martins da Silva, A; Packman, J; Planté-Bordeneuve, V; Schmidt, HH; Suhr, OB; Trigo, P; Waddington Cruz, M; Wilson, A | 1 |
| de Carvalho, M | 1 |
35 review(s) available for benzoxazoles and Amyloid Neuropathy Type 1
| Article | Year |
|---|---|
[Diagnosis and treatment of cardiac transthyretin amyloidosis. Innovative therapy with tafamidis.]
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Humans; Therapies, Investigational | 2022 |
Impact of Tafamidis on Survival in a Real-World Community-Based Cohort.
Topics: Aged, 80 and over; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Female; Heart Failure; Humans; Male; Observational Studies as Topic; Prospective Studies | 2022 |
Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Humans; Prealbumin | 2023 |
[Transthyretin amyloid cardiomyopathy].
Topics: Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Heart Failure; Humans; Prealbumin; Stroke Volume; Tomography, X-Ray Computed | 2023 |
Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review.
Topics: Amyloid Neuropathies, Familial; Autonomic Nervous System Diseases; Benzoxazoles; Humans; Polyneuropathies | 2019 |
Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
Topics: Amyloid Neuropathies, Familial; Amyloidosis; Arrhythmias, Cardiac; Benzoates; Benzoxazoles; Biopsy; Cardiac Pacing, Artificial; Cardiomyopathies; Diflunisal; Disease Progression; Early Diagnosis; Early Medical Intervention; Echocardiography; Electrocardiography; Heart Failure; Humans; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Magnetic Resonance Imaging; Oligonucleotides; Prealbumin; Prognosis; Proteasome Inhibitors; Pyrazoles; Radionuclide Imaging; RNA, Small Interfering | 2020 |
The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy.
Topics: Adult; Amyloid Neuropathies, Familial; Bayes Theorem; Benzoxazoles; Female; Humans; Male; Middle Aged; Network Meta-Analysis; Oligonucleotides; Polyneuropathies; RNA, Small Interfering | 2020 |
Pharmacological treatment for familial amyloid polyneuropathy.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Disease Progression; Humans; Oligonucleotides; Patient Dropouts; Quality of Life; Randomized Controlled Trials as Topic; RNA, Small Interfering | 2020 |
Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Humans; Liver Transplantation; RNA, Small Interfering | 2020 |
Hereditary transthyretin amyloidosis: current treatment.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Biomarkers; Clinical Trials as Topic; Disease Progression; Humans; Oligonucleotides, Antisense; Quality of Life | 2020 |
[Transthyretin cardiac amyloidosis].
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Echocardiography; Electrocardiography; Humans | 2020 |
Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence-Based Recommendations.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Cardiovascular Agents; Genetic Therapy; Humans | 2020 |
A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Topics: Amyloid Neuropathies, Familial; Animals; Benzoxazoles; Cardiomyopathies; Cardiovascular Agents; Diflunisal; Genetic Predisposition to Disease; Humans; Mutation; Oligonucleotides; Phenotype; Prealbumin; RNA, Small Interfering; Treatment Outcome | 2021 |
Updates in Cardiac Amyloidosis Diagnosis and Treatment.
Topics: Amyloid Neuropathies, Familial; Amyloidosis; Benzoxazoles; Cardiomyopathies; Heart Failure; Humans; Immunoglobulin Light-chain Amyloidosis | 2021 |
Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.
Topics: Aging; Alkylating Agents; Amyloid; Amyloid Neuropathies, Familial; Amyloidosis; Antibodies, Monoclonal; Benzoates; Benzoxazoles; Bridged Bicyclo Compounds, Heterocyclic; Cardiomyopathies; Catechol O-Methyltransferase Inhibitors; Heart Transplantation; Humans; Immunomodulating Agents; Oligonucleotides; Proteasome Inhibitors; Protein Folding; Pyrazoles; RNA, Small Interfering; Stem Cell Transplantation; Sulfonamides; Tolcapone | 2021 |
The Ultrastructure of Tissue Damage by Amyloid Fibrils.
Topics: Alzheimer Disease; Amyloid; Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Myocardium; Neuroprotective Agents; Oligonucleotides; Peripheral Nerves; Prealbumin; Prion Diseases; RNA, Small Interfering | 2021 |
Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Topics: Administration, Oral; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Clinical Trials, Phase III as Topic; Disease Management; Disease Progression; Humans; Randomized Controlled Trials as Topic | 2017 |
Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Topics: Algorithms; Amyloid Neuropathies, Familial; Benzoxazoles; Carpal Tunnel Syndrome; Humans; Japan; Liver Transplantation; Methionine; Mutation; Valine | 2018 |
An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Polyneuropathies; Quality of Life; Randomized Controlled Trials as Topic; RNA, Small Interfering; Surveys and Questionnaires | 2019 |
Tafamidis for the treatment of transthyretin amyloidosis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Global Health; Heart Failure; Humans; Survival Rate | 2019 |
Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Biomarkers; Cardiomyopathies; Diagnosis, Differential; Echocardiography; Electrocardiography; Humans; Magnetic Resonance Imaging; Oligonucleotides; Radionuclide Imaging; RNA, Small Interfering | 2019 |
Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
Topics: Amyloid Neuropathies; Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Female; Humans; Male; Oligonucleotides; Prealbumin; Precision Medicine; Randomized Controlled Trials as Topic; RNA, Small Interfering; Treatment Outcome | 2019 |
Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Clinical Trials as Topic; Disease Progression; Drug Approval; Humans; Mutation; Polyneuropathies; Prealbumin; Quality of Life | 2019 |
Treatment of cardiac transthyretin amyloidosis: an update.
Topics: Amyloid; Amyloid Neuropathies; Amyloid Neuropathies, Familial; Benzoxazoles; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Heart Failure; Heart Transplantation; Humans; Liver Transplantation; Mutation; Oligonucleotides; Prealbumin; RNA, Small Interfering; Stroke Volume | 2019 |
Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
Topics: Age Factors; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Delayed Diagnosis; Diagnostic Errors; Early Diagnosis; Early Medical Intervention; Heart Failure; Humans; Stroke Volume | 2019 |
[Familial amyloid polyneuropathies: therapeutic issues].
Topics: Amyloid Neuropathies, Familial; Antibodies, Monoclonal; Benzoxazoles; Clinical Trials as Topic; Diflunisal; Disease Progression; Doxycycline; Drug Therapy, Combination; Genetic Therapy; Heart Failure; Heart Transplantation; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Transplantation; Myocardium; Oligonucleotides, Antisense; Renal Dialysis; RNA Interference; Serum Amyloid P-Component; Taurochenodeoxycholic Acid | 2012 |
FAP neuropathy and emerging treatments.
Topics: Amyloid Neuropathies, Familial; Animals; Benzoxazoles; Gene Silencing; Humans; Liver Transplantation; Mutation; Prealbumin | 2014 |
Recent progress in the understanding and treatment of transthyretin amyloidosis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Genetic Therapy; Humans; Liver Transplantation; Oligonucleotides, Antisense; Prealbumin; RNA, Small Interfering | 2014 |
Tafamidis: a review of its use in familial amyloid polyneuropathy.
Topics: Adult; Amyloid Neuropathies, Familial; Benzoxazoles; Humans | 2014 |
Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Biomarkers; Cardiomyopathies; Cyclooxygenase Inhibitors; Defibrillators, Implantable; Diflunisal; Doxycycline; Heart Failure; Humans; Oligonucleotides, Antisense; Organ Transplantation; Pacemaker, Artificial; RNA, Small Interfering | 2015 |
Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Humans; Mutation; Prealbumin | 2015 |
[Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Amyloid; Amyloid Neuropathies, Familial; Benzoxazoles; Diagnosis, Differential; Diflunisal; Early Diagnosis; Female; Genes, Dominant; Humans; Liver Transplantation; Male; Middle Aged; Mutation; Prealbumin | 2014 |
The transthyretin amyloidoses: advances in therapy.
Topics: Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-Steroidal; Benzoxazoles; Doxycycline; Echocardiography; Humans; Liver Transplantation; Molecular Targeted Therapy; Prealbumin; Prognosis; RNA, Small Interfering; Taurochenodeoxycholic Acid | 2015 |
TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Clinical Trials, Phase III as Topic; Diflunisal; Disease Progression; Gene Silencing; Humans; Liver Transplantation; Prealbumin; Receptors, Albumin | 2016 |
Tafamidis for transthyretin amyloidosis.
Topics: Amyloid Neuropathies, Familial; Animals; Benzoxazoles; Genotype; Humans; Mutation; Neuroprotective Agents; Prealbumin; Randomized Controlled Trials as Topic | 2012 |
22 trial(s) available for benzoxazoles and Amyloid Neuropathy Type 1
| Article | Year |
|---|---|
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Hospitalization; Humans; Prealbumin | 2022 |
Estimating the Effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III Patients with Transthyretin Amyloid Cardiomyopathy in the Presence of Death.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Hospitalization; Humans; Prealbumin | 2022 |
The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 × 20-mg Capsules in Healthy Volunteers.
Topics: Administration, Oral; Adult; Amyloid Neuropathies; Amyloid Neuropathies, Familial; Benzoxazoles; Brazil; Canada; Cardiomyopathies; Cross-Over Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Compounding; Fasting; Female; Healthy Volunteers; Humans; Japan; Male; Middle Aged; Prealbumin; Safety; Therapeutic Equivalency; United States | 2020 |
Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis.
Topics: Adult; Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Female; Humans; Male; Middle Aged; Quality of Life; RNA, Small Interfering; Surveys and Questionnaires | 2020 |
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Heart Failure; Humans; Prealbumin | 2021 |
Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Cost of Illness; Female; Humans; Male; Patient Reported Outcome Measures; Quality of Life; Self Efficacy; Social Participation | 2021 |
Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Topics: Aged; Amyloid Neuropathies, Familial; Amyloidosis; Arrhythmias, Cardiac; Benzoxazoles; Cardiomyopathies; Cardiovascular Diseases; Cause of Death; Death, Sudden, Cardiac; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; Prealbumin; Proportional Hazards Models; Stroke | 2021 |
Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Humans; Prealbumin | 2022 |
Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Disease Progression; Female; Humans; Male; Middle Aged; Polyneuropathies; Prealbumin; Treatment Outcome | 2017 |
Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.
Topics: Adult; Amyloid; Amyloid Neuropathies, Familial; Benzoxazoles; Biomarkers; Creatinine; Cystatin C; Drug Administration Schedule; Female; Gene Expression; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Mutation; Nephritis; Prealbumin; Prospective Studies; Proteinuria | 2017 |
Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years.
Topics: Adult; Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Female; Humans; Longitudinal Studies; Male; Middle Aged; Quality of Life | 2017 |
Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.
Topics: Adult; Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Disease Progression; Double-Blind Method; Female; Genotype; Humans; Lower Extremity; Male; Middle Aged; Mutation; Treatment Outcome | 2018 |
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Disease Progression; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prealbumin; Quality of Life; Survival Analysis; Walk Test | 2018 |
Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Case-Control Studies; Echocardiography; Hospitalization; Humans; Mutation; Placebos; Prealbumin; Survival Analysis | 2019 |
Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.
Topics: Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Disease Progression; Humans; Middle Aged | 2013 |
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.
Topics: Adult; Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; International Cooperation; Male; Methionine; Middle Aged; Mutation; Prealbumin; Quality of Life; Time Factors; Valine; Young Adult | 2013 |
Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.
Topics: Adult; Aged; Amyloid; Amyloid Neuropathies, Familial; Benzoxazoles; Disease Progression; Europe; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Mutation; Phenotype; Prealbumin; Time Factors; Treatment Outcome; United States | 2013 |
Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.
Topics: Adult; Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Europe; Female; Fibrosis; Genetic Predisposition to Disease; Heart Failure; Humans; Male; Middle Aged; Mutation; Myocardium; Phenotype; Prealbumin; Risk Factors; Time Factors; Treatment Outcome; United States | 2015 |
Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Topics: Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Mutation; Myocardium; Prealbumin; Protein Folding; Protein Multimerization; Protein Stability; Protein Structure, Quaternary; Time Factors; Treatment Outcome; United States | 2015 |
Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
Topics: Adult; Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Body Mass Index; Echocardiography; Female; Follow-Up Studies; Humans; Japan; Male; Methionine; Middle Aged; Pharmacogenetics; Prealbumin; Valine; Young Adult | 2016 |
Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
Topics: Adult; Aged; Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-Steroidal; Benzoxazoles; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Prospective Studies; Secondary Prevention | 2016 |
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Topics: Adolescent; Adult; Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Double-Blind Method; Humans; Male; Middle Aged; Neuroprotective Agents; Polymorphism, Single Nucleotide; Prealbumin; Quality of Life; Severity of Illness Index | 2012 |
83 other study(ies) available for benzoxazoles and Amyloid Neuropathy Type 1
| Article | Year |
|---|---|
Compassionate drug use for patients with transthyretin amyloid cardiomyopathy.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathy, Restrictive; Compassionate Use Trials; Drug Approval; Drugs, Investigational; Heart Failure; Humans; Magnetic Resonance Imaging, Cine; Myocardial Perfusion Imaging; Treatment Outcome | 2021 |
Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary.
Topics: Adult; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Heart Failure; Humans; Language; Prealbumin; Quality of Life | 2022 |
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Topics: Aged; Aged, 80 and over; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prealbumin; Proportional Hazards Models; Time | 2022 |
Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Liver Transplantation; Prealbumin; RNA, Small Interfering | 2022 |
[Practice guideline for the treatment of familial amyloid polyneuropathy].
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Prealbumin; Quality of Life; Treatment Outcome | 2022 |
[Specific pharmacological treatment guide for transthyretin amyloid cardiomyopathy, 2021].
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Diflunisal; Doxycycline; Humans; Prealbumin; Ursodeoxycholic Acid | 2022 |
Tafamidis and its stabilizing effects on transthyretin tetramers, the heart and eventually, scientific evidence.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Myocardium; Prealbumin | 2022 |
Early Experience of Tafamidis Treatment in Japanese Patients With Wild-Type Transthyretin Cardiac Amyloidosis From the Kochi Amyloidosis Cohort.
Topics: Aged; Aged, 80 and over; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Humans; Japan; Prealbumin; Stroke Volume; Ventricular Function, Left | 2022 |
What is this image? 2022 image 1 result: radiologic improvement of transthyretin cardiac amyloidosis after treatment with tafamidis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Humans; Prealbumin | 2022 |
Response by Elliott et al to Letter Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Heart Failure; Humans; Prealbumin | 2022 |
Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Heart Failure; Humans; Prealbumin | 2022 |
Understanding Changes in Functional Capacity After TTR Stabilization in Patients With Transthyretin Cardiac Amyloidosis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Heart Failure; Humans; Prealbumin | 2022 |
Redefining Prognosis of Transthyretin Cardiomyopathy in the Tafamidis Era.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Heart Failure; Humans; Prealbumin; Prognosis | 2022 |
Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Male; Polyneuropathies; Prealbumin | 2023 |
Regression of left ventricular hypertrophy after tafamidis therapy in a patient with transthyretin amyloidosis variant.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Hypertrophy, Left Ventricular; Prealbumin | 2022 |
Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Disease Progression; Humans; Prealbumin | 2023 |
Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Humans; Prealbumin | 2023 |
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Liver Transplantation; Middle Aged; Prealbumin; Retrospective Studies | 2023 |
New Drugs Treat Rare Heart Disease Caused by Transthyretin-Mediated Amyloidosis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Heart Diseases; Humans | 2019 |
Biophysical characterization and modulation of Transthyretin Ala97Ser.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Binding Sites; Biophysical Phenomena; Calorimetry; Humans; Magnetic Resonance Spectroscopy; Mutation; Prealbumin | 2019 |
Transthyretin Amyloidosis with Gastrointestinal Manifestation: a Case Report.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Chronic Disease; Diagnosis, Differential; Diarrhea; DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Mutation; Prealbumin; Predictive Value of Tests | 2019 |
A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Humans | 2019 |
Advantages and Emerging Problems of Novel Treatments for Transthyretin Cardiac Amyloidosis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Prealbumin | 2019 |
Tafamidis-A Pricey Therapy for a Not-So-Rare Condition.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cost-Benefit Analysis; Drug Approval; Health Policy; Humans; Randomized Controlled Trials as Topic; United States | 2020 |
Hereditary transthyretin amyloidosis caused by the rare Phe33Leu mutation.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Combined Modality Therapy; Diagnosis, Differential; Heart Transplantation; Humans; Leucine; Male; Middle Aged; Mutation; Phenylalanine; Prealbumin | 2020 |
Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Humans; Prealbumin | 2019 |
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
Topics: Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Cost-Benefit Analysis; Female; Humans; Male; Quality of Life | 2020 |
Initial Monthly Cost of Tafamidis-the Real Price for Patients.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans | 2020 |
Initial Monthly Cost of Tafamidis-the Real Price for Patients-Reply.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans | 2020 |
[Experience with tafamidis in a patient with transthyretin amyloidosis].
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Prealbumin | 2020 |
Motor excitability measurements in early stage familial amyloid polyneuropathy: The influence of tafamidis treatment.
Topics: Adult; Amyloid Neuropathies, Familial; Benzoxazoles; Female; Humans; Male; Median Nerve; Nerve Fibers; Neural Conduction; Neuroprotective Agents; Treatment Outcome | 2020 |
Characteristics of Patients with Hereditary Transthyretin Amyloidosis and an Evaluation of the Safety of Tafamidis Meglumine in Japan: An Interim Analysis of an All-case Postmarketing Surveillance.
Topics: Adolescent; Adult; Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Disease Progression; Female; Humans; Japan; Male; Middle Aged; Young Adult | 2020 |
Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Topics: Amyloid; Amyloid Neuropathies, Familial; Benzoates; Benzoxazoles; Cardiomyopathies; Diflunisal; Humans; Kinetics; Prealbumin; Protein Aggregates; Protein Binding; Protein Multimerization; Protein Subunits; Pyrazoles; Tolcapone | 2021 |
Conventional Molecular Dynamics and Metadynamics Simulation Studies of the Binding and Unbinding Mechanism of TTR Stabilizers AG10 and Tafamidis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Molecular Dynamics Simulation; Prealbumin | 2020 |
Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Cost-Benefit Analysis; Humans; Prealbumin | 2020 |
Letter by Rozenbaum et al Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Cost-Benefit Analysis; Humans; Prealbumin | 2020 |
Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; France; Heart Failure; Humans | 2021 |
Population pharmacokinetic modelling and simulation of tafamidis in healthy subjects and patients with transthyretin amyloidosis.
Topics: Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Healthy Volunteers; Humans | 2021 |
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cost of Illness; Drug Costs; Health Care Costs; Hospitalization; Humans; Oligonucleotides; RNA, Small Interfering; Spain | 2021 |
Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Hospitalization; Humans; Models, Statistical; Survival Analysis | 2021 |
[Update of tafamidis for the treatment of transthyretin cardiac amyloidosis].
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Prealbumin | 2021 |
False Positive 99mTc-Pyrophosphate Scanning Leading to Inappropriate Tafamidis Prescriptions.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Predictive Value of Tests; Prescriptions; Technetium Tc 99m Pyrophosphate | 2021 |
Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Prealbumin | 2021 |
Discredited legacy: Stigma and familial amyloid polyneuropathy in Northwestern Portugal.
Topics: Adult; Amyloid Neuropathies, Familial; Benzoxazoles; Female; Genetic Diseases, Inborn; Humans; Male; Middle Aged; Portugal; Qualitative Research; Reproductive Behavior; Social Stigma; Surveys and Questionnaires | 2017 |
Disruption of blood-nerve barriers in hereditary transthyretin (ATTR) amyloidosis.
Topics: Adult; Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Cell Survival; Female; Humans; Male; Middle Aged; Mutation; Plasma | 2017 |
Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats.
Topics: Amyloid Neuropathies, Familial; Animals; Benzoxazoles; Brain; Caco-2 Cells; Humans; Liver; Male; Microsomes, Liver; Organ Specificity; Rats; Rats, Sprague-Dawley | 2018 |
Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cysts; Humans; Liver Diseases; Liver Transplantation; Male; Middle Aged; Mutation; Prealbumin; Treatment Outcome | 2017 |
Unwanted road to anaemia in transthyretin familial amyloid polyneuropathy may continue irrespective of tafamidis treatment.
Topics: Amyloid Neuropathies, Familial; Anemia; Benzoxazoles; Blood Chemical Analysis; Disease Progression; Female; Humans; Longitudinal Studies; Male; Middle Aged; Retrospective Studies | 2018 |
Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Topics: Adult; Amyloid Neuropathies, Familial; Benzoxazoles; Blindness; Brain Ischemia; Cerebrovascular Disorders; Disease Progression; Eye Diseases; Female; Genetic Predisposition to Disease; Humans; Intracranial Hemorrhages; Magnetic Resonance Imaging; Mutation; Phenotype; Prealbumin; Siderosis; Treatment Failure; Ultrasonography | 2018 |
Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients.
Topics: Adult; Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Disease Progression; Female; Humans; Liver Transplantation; Male; Middle Aged; Neural Conduction; Polyneuropathies; Time Factors; Treatment Outcome | 2018 |
Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients.
Topics: Administration, Oral; Adult; Amyloid Neuropathies, Familial; Benzoxazoles; Cerebrospinal Fluid; Chromatography, High Pressure Liquid; Female; Humans; Liver Transplantation; Male; Mutation; Prealbumin; Vitreous Body | 2018 |
[What gnaws at the heart and gets on the nerves].
Topics: Aged; Amyloid; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Drug Approval; Humans; Middle Aged; Mutation; Polyneuropathies; Prealbumin; Quality of Life | 2018 |
Transthyretin Stabilizer Is Associated With Expanding Apical Sparing Area and Improving Global Cardiac Function in a Patient With Wild-Type Cardiac Amyloidosis.
Topics: Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Heart; Humans; Magnetic Resonance Angiography; Male; Treatment Outcome | 2019 |
Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.
Topics: Adult; Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Disease Progression; Female; Follow-Up Studies; Humans; Liver Transplantation; Male; Middle Aged | 2018 |
Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy.
Topics: Amyloid Neuropathies, Familial; Animals; Benzoxazoles; Brazil; Cardiomyopathies; Diagnosis, Differential; Humans; Oligonucleotides; Randomized Controlled Trials as Topic; RNA, Small Interfering | 2018 |
Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Topics: Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Biopsy; Cardiomyopathies; Electrocardiography; Follow-Up Studies; Humans; Magnetic Resonance Imaging, Cine; Male; Myocardium | 2019 |
Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Diuretics; Echocardiography; Genes, Dominant; Humans; Male; Middle Aged; Mutation; Prealbumin; Radionuclide Imaging; Treatment Outcome | 2018 |
Tafamidis for Transthyretin Amyloid Cardiomyopathy.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Humans; Prealbumin | 2019 |
Tafamidis for Transthyretin Amyloid Cardiomyopathy.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Humans; Prealbumin | 2019 |
Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Eye Diseases; Humans; Mutation, Missense; Prealbumin; Protein Aggregation, Pathological | 2019 |
Electrochemical skin conductance in hereditary amyloidosis related to transthyretin V30M - a promising tool to assess treatment efficacy?
Topics: Adult; Amyloid Neuropathies, Familial; Benzoxazoles; Case-Control Studies; Electrochemical Techniques; Female; Follow-Up Studies; Galvanic Skin Response; Humans; Male; Middle Aged; Mutation; Neural Conduction; Prealbumin; Prognosis; Prospective Studies | 2018 |
Tafamidis dramatically improved severe proteinuria in a patient with TTR V30M hereditary ATTR amyloidosis.
Topics: Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Male; Middle Aged; Mutation, Missense; Prealbumin; Proteinuria; Treatment Outcome | 2019 |
Letter to the editor concerning the article: "An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Polyneuropathies; Prealbumin; RNA, Small Interfering | 2019 |
Response to the letter to the editor on "an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Polyneuropathies; Prealbumin; RNA, Small Interfering | 2019 |
[The ATTR-ACT trial].
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2019 |
Predictive model of response to tafamidis in hereditary ATTR polyneuropathy.
Topics: Adult; Aged; Aged, 80 and over; Amyloid Neuropathies, Familial; Benzoxazoles; Biomarkers; Cohort Studies; Demography; Female; Humans; Longitudinal Studies; Male; Middle Aged; Models, Biological; Prealbumin; Sex Factors; Treatment Outcome; Young Adult | 2019 |
Real-world versus trial patients with transthyretin amyloid cardiomyopathy.
Topics: Aged; Aged, 80 and over; Amyloid Neuropathies, Familial; Angiotensin-Converting Enzyme Inhibitors; Benzoxazoles; Cardiomyopathies; Cardiovascular Agents; Clinical Trials as Topic; Diuretics; Female; Humans; Male; Rare Diseases | 2019 |
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Male; Neuroprotective Agents; Prealbumin | 2013 |
Tafamidis (Vyndaqel): a light for FAP patients.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Binding Sites; Drug Design; Humans; Mutation; Prealbumin; Protein Binding; Protein Structure, Tertiary | 2013 |
[Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Humans; Liver Transplantation; Molecular Targeted Therapy; Prealbumin; Protein Multimerization | 2014 |
A woman with a rare p.Glu74Gly transthyretin mutation presenting exclusively with a rapidly progressive neuropathy: a case report.
Topics: Adult; Amyloid Neuropathies, Familial; Benzoxazoles; Disease Progression; Fatal Outcome; Female; Genetic Linkage; Glutamic Acid; Glycine; Humans; Liver Transplantation; Mutation, Missense; Pedigree; Prealbumin | 2014 |
Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
Topics: Adult; Amino Acid Substitution; Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Hypesthesia; Liver Transplantation; Male; Muscle Weakness; Mutation; Neuroprotective Agents; Prealbumin | 2015 |
Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
Topics: Aged, 80 and over; Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Drug Dosage Calculations; Drug Monitoring; Escherichia coli; Gene Expression; Humans; Kinetics; Male; Neuroprotective Agents; Prealbumin; Precision Medicine; Protein Stability; Recombinant Proteins | 2015 |
Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
Topics: Adult; Aged; Aged, 80 and over; Amyloid Neuropathies, Familial; Benzoxazoles; Disease Progression; Female; Follow-Up Studies; Humans; Italy; Longitudinal Studies; Male; Middle Aged; Mutation; Prealbumin; Prognosis; Severity of Illness Index; Treatment Outcome | 2016 |
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
Topics: Amyloid Neuropathies, Familial; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoxazoles; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Gene Expression; Humans; Liver; Macaca fascicularis; Male; Mice; Mice, Transgenic; Prealbumin; RNA Interference; RNA, Messenger; RNA, Small Interfering | 2016 |
[Presentations of transthyretin associated familial amyloid polyneuropathy in Argentina].
Topics: Adult; Amyloid Neuropathies, Familial; Argentina; Benzoxazoles; Fatal Outcome; Female; Humans; Liver Transplantation; Male; Middle Aged; Mutation; Prealbumin; Retrospective Studies | 2016 |
Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.
Topics: Adult; Amyloid Neuropathies, Familial; Benzoxazoles; Biomarkers; Blood Cells; Cohort Studies; Female; Gene Expression; Gene Expression Profiling; Heterozygote; Humans; Inflammation; Male; Prealbumin; RNA; Sex Characteristics | 2016 |
Tafamidis in hereditary ATTR amyloidosis - our experience on monitoring the ocular manifestations.
Topics: Amyloid; Amyloid Neuropathies, Familial; Benzoxazoles; Disease Progression; Female; Humans; Iris; Male; Middle Aged; Optic Disk; Prealbumin; Protein Aggregates; Retinal Pigment Epithelium; Vitreous Body | 2016 |
Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
Topics: Adult; Aged; Aged, 80 and over; Amyloid Neuropathies, Familial; Benzoxazoles; Body Mass Index; Disease Progression; Female; Follow-Up Studies; Hematologic Agents; Humans; Male; Middle Aged; Neural Conduction; Time Factors; Treatment Outcome | 2017 |
Treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a case report.
Topics: Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Male | 2017 |
[Treatment of familial amyloid polyneuropathy].
Topics: Amyloid; Amyloid Neuropathies, Familial; Arrhythmias, Cardiac; Benzoxazoles; Early Diagnosis; Follow-Up Studies; Heart Transplantation; Humans; Kidney Transplantation; Liver Transplantation; Mutation; Prealbumin; Quality of Life; RNA Interference; RNA, Small Interfering | 2012 |
A designer drug for amyloid polyneuropathy.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Male; Neuroprotective Agents; Prealbumin | 2012 |
Is it better than it seems or just good enough? The tafamidis saga.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Humans; Mutation; Neuroprotective Agents; Prealbumin | 2012 |